Methods for generating high titer helper-free preparations of released recombinant AAV vectors

• US 6,989,264 B2
• Filed: 10/30/2001
• Issued: 01/24/2006
• Est. Priority Date: 09/05/1997
• Status: Expired due to Term

• Current Assignee: Targeted Genetics Corporation (Innoviva, Inc.)
• Original Assignee: Targeted Genetics Corporation (Innoviva, Inc.)
• Inventors: Aranha, Ian L., Wilkins, Perry C., Fung, Victor P., Reynolds, Thomas C., Takeya, Ryan K., Atkinson, Edward M.
• Primary Examiner(s): Housel, James
• Assistant Examiner(s): Hill, Myron G.
• Application Number:
  US10/016,767
• Publication Number:
  US 20020127582A1
• Time in Patent Office: 1,547 Days
• Field of Search: 435/41, 435/42, 435/235.1, 435/239, 435/325, 435/320.1
• US Class Current: 435/239
• CPC Class Codes: A61K 48/0091 Purification or manufacturing processes for gene therapy compositions
• CPC Class Codes: C07C 2/32 as complexes, e.g. acetyl-acetonates complexes of salts of acids of halogen C07C2/20
• CPC Class Codes: C07C 2531/22 Organic complexes
• CPC Class Codes: C07D 207/32 with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• CPC Class Codes: C07D 207/34 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• CPC Class Codes: C07D 207/50 Nitrogen atoms
• CPC Class Codes: C07D 295/30 non-acylated
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 409/14 containing three or more hetero rings
• CPC Class Codes: C07F 15/045 without a metal-carbon linkage
• CPC Class Codes: C07F 7/0812 comprising a heterocyclic ring
• CPC Class Codes: C07F 9/572 Five-membered rings
• CPC Class Codes: C07F 9/58 Pyridine rings
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2750/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/14151 Methods of production or purification of viral material
• CPC Class Codes: C12N 2750/14152 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterologous (i.e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. The invention described herein provides methods of producing rAAV particles by culturing producer cells under conditions, such as temperature and pH, that promote release of virus. Also provided is a quantitative, high-throughput assay useful in the assessment of viral infectivity and replication, as well as in the screening of agent that affect viral infectivity and/or replication.

Claims

1. A method of isolating a population of rAAV particles, comprising the steps of:

(a) chromatographing an AAV producer cell lysate containing rAAV particles on a positively-charged anion exchange resin;

or chromatographing an AAV producer cell lysate containing rAAV particles on a negatively-charged cation exchange resin, and collecting a fraction containing rAAV particles; and

(b) chromatographing the fraction of step (a) on exchange resin opposite in charge to that used in step (a) and collecting a fraction containing rAAV particles;

whereby a purified population of rAAV particles is generated.

2. The method of claim 1, wherein chromatographing on a positively-charged anion exchange resin is performed before chromatographing on a negatively-charged cation exchange resin.

3. The method of claim 1, wherein chromatographing on a negatively-charged cation exchange resin is performed before chromatographing on a positively-charged anion exchange resin.

4. The method of claim 3, further comprising step (c) of chromatographing the fraction containing rAAV particles from step (b) on a negatively-charged cation exchange resin.

5. The method of claim 4, wherein heparin sulfate is used for step (c).

6. The method of claim 1, further comprising the step of subjecting the producer cells to tangential flow filtration.

7. The method of claim 1, wherein the lysate is subjected to tangential flow filtration prior to step (a).

8. The method of claim 1, wherein the fraction containing rAAV particles from step (a) or step (b) is subiect to tangential flow filtration.

9. The method of claim 1, wherein said anion exchange resin is an N-charged amino or imino resin.

10. The method of claim 9, wherein said anion exchange resin is selected from the group consisting of a diethylaminoethyl (DEAE) resin, a trimethylaminoethyl (TMAE) resin, a quaternary amine resin and a polyethyleneimine (PEI) resin.

11. The method of claim 1, wherein said cation exchange resin is a sulfo-, phospho- or carboxy-based cationic resin.

12. The method of claim 11, wherein said cation exchange resin is selected from the group consisting of a heparin sulfate (HS) resin, a sulphopropyl (SP) resin, and a carboxymethyl (CM) resin.

13. The method of claim 1, wherein the producer cell is cultured under suspension conditions.

70. The method of claim 11, wherein said cation exchange resin is a sulfo-based cationic resin.

71. The method of claim 11, wherein said cation exchange resin is a phospho-based cationic resin.

72. The method of claim 11, wherein said cation exchange resin is a carboxy-based cationic resin.

73. The method of claim 2, wherein the anion exchange resin is a polyethyleneimine (PEI) resin and the cation exchange resin is a sulphopropyl (SP) resin.

74. The method of claim 3, wherein the cation exchange resin is a sulphopropyl (SP) resin and the anion exchange resin is a polyethyleneimine (PEI) resin.

75. The method of claim 74, further comprising step (c) of chromatographying the fraction containing rAAV particles from step (b) on a heparin sulfate resin.

14. A method of isolating a population of rAAV particles, comprising the steps of:

(a) chromatographing an AAV producer cell culture supernatant which contains rAAV particles on a positively-charged anion exchange resin or chromatographing an AAV producer cell culture supernatant containing rAAV particles on a negatively-charged cation exchange resin, and collecting a fraction containing rAAV particles; and

(b) chromatographing the fraction of step (a) on exchange resin opposite in charge to that used in step (a) and collecting a fraction containing rAAV particles;

whereby a purified population of rAAV particles is generated.

15. The method of claim 14, wherein chromatographing on a positively-charged anion exchange resin is performed before chromatographing on a negatively-charged cation exchange resin.

16. The method of claim 14, wherein chromatographing on a negatively-charged cation exchange resin is performed before chromatographing on a positively-charged anion exchange resin.

17. The method of claim 16, further comprising step (c) of chromatographing the fraction containing rAAV particles from step (b) on a negatively-charged cation exchange resin.

18. The method of claim 17 wherein heparin sulfate is used for step (c).

19. The method of claim 14, further comprising the step of subjecting the culture supernatant to tangential flow filtration prior to step (a).

20. The method of claim 14, wherein the faction containing rAAV particles from step (a) or step (b) is subiect to tangential flow filtration.

21. The method of claim 14, wherein said anion exchange resin is an N-charged amino or imino resin.

22. The method of claim 21, wherein said anion exchange resin is selected from the group consisting of a diethylaminoethyl (DEAE) resin, a trimethylaminoethyl (TMAE) resin, a quaternary amine resin and a polyethyleneimine (PEI) resin.

23. The method of claim 14, wherein said cation exchange resin is a sulfo-, phospho- or carboxy-based cationic resin.

24. The method of claim 23, wherein said cation exchange resin is selected from the group consisting of a heparin sulfate (HS) resin, a sulphopropyl (SP) resin, and a carboxymethyl (CM) resin.

25. The method of claim 14, wherein the producer cell is cultured under suspension conditions.

76. The method of claim 23, wherein said cation exchange resin is a sulfo-based cationic resin.

77. The method of claim 23, wherein said cation exchange resin is a phospho-based cationic resin.

78. The method of claim 23, wherein said cation exchange resin is a carboxy-based cationic resin.

79. The method of claim 23, wherein the anion exchange resin is a polyethyleneimine (PE) resin and the cation exchange resin is a sulphopropyl (SP) resin.

80. The method of claim 16, wherein the cation exchange resin is a sulphopropyl (SP) resin and the anion exchange resin is a polyethyleneimine (PEI) resin.

81. The method of claim 80, further comprising step (c) of chromatographying the fraction containing rAAV particles fiom step (b) on a heparin sulfate resin.

26. A method of generating a population of recombinant adeno-associated virus (rAAV) particles, comprising the steps of:

a) incubating an AAV producer cell under conditions that are permissive for replication of AAV;

said producer cell comprising;

(i) one or more AAV packaging genes, wherein each said AAV packaging gene encodes an AAV replication or encapsidation protein;

(ii) a recombinant AAV (rAAV) vector that comprises a heterologous non-AAV polynucleotide flanked by at least one AAV inverted terminal repeat (ITR); and

(iii) a helper virus for AAV;

b) lysing the producer cell after the incubation of step a) to produce an AAV producer cell lysate;

c) chromatographing the AAV producer cell lysate of step b) on at least one positively-charged anion exchange resin; and

d) purifing the chromatographic fractions containing rAAV particles of step c) by cation exchange chromatography to generate a purified population of rAAV vector particles.

27. A method of generating a population of rAAV particles according to claim 26, wherein said rAAV vector comprises a heterologous non-AAV polynucleotide flanked by two AAV inverted terminal repeats (ITRs).

28. A method of generating a population of rAAV particles according to claim 26, wherein said AAV producer cell comprises at least one AAV packaging gene that is stably integrated into the genome of said AAV producer cell.

29. A method of generating a population of rAAV particles according to claim 26, wherein the helper virus is introduced into the producer cell already introduced with the AAV packaging gene(s) and the rAAV vector.

30. A method of generating a population of rAAV particles according to claim 26, wherein the rAAV vector and the helper virus are introduced simultaneously or sequentially into the producer cell already introduced with the AAV packaging gene(s).

31. A method of generating a population of rAAV particles according to claim 26, wherein the AAV packaging gene(s) and the rAAV vector are introduced simultaneously or sequentially into the producer cell already introduced with the helper virus.

32. A method of generating a population of rAAV particles according to claim 26, wherein said AAV producer cell comprises an AAV rep gene and an AAV cap gene.

33. A method of generating a population of rAAV particles according to claim 26, wherein said AAV rep gene and AAV cap gene are stably integrated into the genome of said AAV producer cell.

34. A method of generating a population of rAAV particles according to claim 26, wherein at least one AAV split-packaging gene is introduced into the producer cell.

35. A method of generating a population of rAAV particles according to claim 26, wherein said helper virus is an adenovirus.

36. A method of generating a population of rAAV particles according to claim 26, wherein said helper virus is a temperature-sensitive helper virus and said step of incubating the producer cell is conducted at a temperature that is permissive for replication of AAV but non-permissive for replication of the temperature-sensitive helper virus.

37. A method of generating a population of rAAV particles according to claim 26, wherein said helper virus is a temperature-sensitive adenovirus.

38. A method of generating a population of rAAV particles according to claim 26, wherein said helper virus is adenovirus Ad-ts149.

39. A method of generating a population of rAAV particles according to claim 26, wherein said AAV producer cell lysate is also affinity purified on a resin having a ligand that is specific for one or more surface molecules present on AAV.

40. A method of generating a population of rAAV particles according to claim 39, wherein the affinity purification is conducted after ion-exchange chromatography.

41. A method of generating a population of rAAV particles according to claim 39, wherein said ligand is an antibody that is specific for a surface molecule present on AAV.

42. A method of generating a population of rAAV particles according to claim 26, wherein the AAV producer cells of step a) are concentrated prior to lysis.

43. A method of generating a population of rAAV particles according to claim 42, wherein the AAV producer cells of step a) are concentrated by centrifugation or by tangential flow filtration prior to lysis.

44. A method of generating a population of rAAV particles according to claim 26, wherein said step of lysing the AAV producer cell is conducted by subjecting the cells to a lytic technique selected from the group consisting of microfluidization, sonication, and freeze-thawing.

45. A method of generating a population of rAAV particles according to claim 44, wherein said step of lysing the AAV producer cell is conducted by subjecting the cells to microfluidization.

46. A method of generating a population of rAAV particles according to claim 26, wherein the AAV producer cell lysate of step b) is treated with a nuclease prior to chromatography.

47. A method of generating a population of rAAV particles according to claim 46, wherein said nuclease is Benzonase.

48. A method of generating a population of rAAV particles according to claim 26, wherein the AAV producer cell lysate of step b) is clarified prior to chromatography.

49. A method of generating a population of rAAV particles according to claim 48, wherein the AAV producer cell lysate of step b) is clarified by filtration or centrifugation prior to chromatography.

50. A method of generating a population of rAAV particles according to claim 26, wherein the AAV producer cells are concentrated prior to lysis, resuspended in a buffer comprising saline at an ionic strength at least that of a 50 mM NaCl solution, lysed, and then clarified by filtration prior to chromatography.

51. A method of generating a population of rAAV particles according to claim 26, wherein chromatographic fractions containing rAAV particles are concentrated by filtration or centrifugation after elution from the chromatographic resin.

52. A method of generating a population of rAAV particles according to claim 26, wherein chromatographic fractions containing rAAV particles are concentrated by tangential flow filtration.

53. A method of generating a population of rAAV particles according to claim 26, wherein said anion exchange resin is an N-charged amino or imino resin.

54. A method of generating a population of rAAV particles according to claim 26, wherein said anion exchange resin is selected from the group consisting of a diethylaninoethyl (DEAE) resin, a trimethylaminoethyl (TMAE) resin, a quaternary amine resin and a polyethyleneimine (PEI) resin.

55. A method of generating a population of rAAV particles according to claim 26, wherein said cation exchange resin is a sulfo-, phospho- or carboxy-based cationic resin.

56. A method of generating a population of rAAV particles according to claim 26, wherein said cation exchange resin is selected from the group consisting of a heparin sulfate (HS) resin, a sulfopropyl (SP) resin, and a carboxymethyl (CM) resin.

57. A method of generating a population of rAAV particles according to claim 26, wherein the producer cell of step a) is an attachment-dependent mammalian cell line.

58. A method of generating a population of rAAV particles according to claim 26, wherein said step a) of incubating the producer cell is conducted in a vessel selected from the group consisting of a tissue culture flask, a roller bottle, a spinner flask, a tank reactor, a fermentor, and a bioreactor.

59. A method of generating a population of rAAV particles according to claim 26, wherein said step a) of incubating the producer cell is conducted using a microcarrier.

60. A method of generating a population of rAAV particles according to claim 58, wherein said bioreactor is a hollow-fiber, packed-bed or fluidized-bed bioreactor.

61. A method of generating a population of rAAV particles according to claim 26, wherein the producer cell of step a) is a suspension-adapted mammalian cell line.

62. A method of generating a population of rAAV particles according to claim 26, wherein said step a) of incubating the producer cell is conducted in a vessel selected from the group consisting of a spinner flask, a tank reactor and an air lift fermentor.

63. A method of generating a population of rAAV particles according to claim 26, wherein said step a) of incubating the producer cell is performed in rAAV medium essentially as shown in Table 2.

64. A method of generating a population of rAAV particles according to claim 26, wherein the producer cells are 293 N3s cells or HeLa S3 cells.

65. A method of generating a population of rAAV particles according to claim 26, wherein step a) is conducted for at least 5 days.

66. A method of generating a population of rAAV particles according to claim 26, wherein step a) of incubating the producer cell is conducted in a multi-liter bioreactor and wherein at least about 10⁹ replicativc units of rAAV per liter of bioreactor volume are isolated after step d).

67. A method of generating a population of recombinant adeno-associated virus (rAAV) particles, comprising the steps of:

a) incubating an AAV producer cell under conditions that are permissive for replication of AAV and which comprise inducing a stress in the AAV producer cell;

wherein said AAV producer cell comprising (i) one or more AAV packaging genes, wherein each said AAV packaging gene encodes an AAV replication or encapsidation protein;

(ii) a recombinant AAV (rAAV) vector that comprises a heterologous non-AAV polynucleotide flanked by at least one AAV inverted terminal repeat (ITR); and

(iii) a helper virus for AAV;

b) lysing the producer cell after the incubation of step a) to produce an AAV producer cell lysate; and

c) purifying the AAV producer cell lysate to generate a population of recombinant adeno-associated virus (rAAV) particles, wherein said purifying step comprises chromatographing the AAV producer cell lysate of step b) on at least one positively-charged anion exchange resin followed by purifying on either a cation exchange resin or by tangential flow filtration to generate a purified population of rAAV vector particles.

68. The method of claim 67, wherein said purifying step c) comprises chromatographing the AAV producer cell lysate of step b) on at least one negatively-charged cation exchange resin followed by purifying on an anion exchange resin.

69. The method of claim 68, wherein the method further comprises a step of purifying the chromatographic fractions containing rAAV particles of step c) by cation exchange resin.